A kernel-based integration of genome-wide data for clinical decision support

Genome Medicine

Volumn 1, Issue 4, 2009, Pages

  Daemen, Anneleen ^a   Gevaert, Olivier ^a   Ojeda, Fabian ^a   Debucquoy, Annelies ^a   Suykens, Johan A K ^a   Sempoux, Christine ^b   Machiels, Jean Pascal ^b   Haustermans, Karin ^a   Moor, Bart De ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 3; ADIPONECTIN; BETA 2 MICROGLOBULIN; CA 19-9 ANTIGEN; CAPECITABINE; CETUXIMAB; CXCL14 CHEMOKINE; CYCLOOXYGENASE 2; CYTOCHROME P450 1B1; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FERRITIN; GELATINASE A; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR TYPE I; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; MUCIN 2; ONCOPROTEIN; PROTEIN RNASEL; PROTEIN VAV3; PROTEOME; SECRETED FRIZZLED RELATED PROTEIN 4; THROMBOPLASTIN; TRANSCRIPTION FACTOR POU4F1; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CLINICAL DECISION MAKING; CLINICAL TRIAL; DNA MICROARRAY; EXTERNAL BEAM RADIOTHERAPY; GENE MAPPING; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOMICS; HUMAN; INFORMATION PROCESSING; KERNEL METHOD; MATHEMATICAL ANALYSIS; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; RECTUM CANCER; RNA TRANSLATION;

EID: 70449481151     PISSN: None     EISSN: 1756994X     Source Type: Journal    
DOI: 10.1186/gm39     Document Type: Article

References (90)

1. Shawe-Taylor J, Cristianini N: Kernel Methods for Pattern Analysis. Cambridge: Cambridge University Press; 2004.
2. Bhaskar H, Hoyle DC, Singh S: Machine learning in bioinformatics: a brief survey and recommendations for practitioners. Comput Biol Med 2006, 36:1104-1125.
3. Suykens JAK, Vandewalle J: Least squares support vector machine classifiers. Neural Processing Lett 1999, 9:293-300.
4. Suykens JAK, Van Gestel T, De Brabanter J, De Moor B, Vandewalle J: Least Squares Support Vector Machines. Singapore: World Scientific; 2002.
5. Cawley GC: Leave-one-out cross-validation based model selection criteria for weighted LS-SVMs. Proc Int Joint Conf on Neural Networks 2006:1661-1668.
6. Alon A, Barkai N, Notterman DA, Gish K, Ybarra S, Mack D, Levine AJ: Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci USA 1999, 96:6745-6750.
7. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537.
8. Cardoso F, van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ: Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008, 26:729-735.
9. Sparano JA: TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 2006, 7:347-350.
10. Sparano JA, Paik S: Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008, 26:721-728.
11. Pinkel D, Albertson DG: Array comparative genomic hybridization and its applications in cancer. Nat Genet 2005, 37:S11-S17.
12. Esteller M: Epigenetics in cancer. N Engl J Med 2008, 358:1148-1159.
13. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H, Shapero MH, Carson AR, Chen W, Cho EK, Dallaire S, Freeman JL, González JR, Gratacòs M, Huang J, Kalaitzopoulos D, Komura D, MacDonald JR, Marshall CR, Mei R, Montgomery L, Nishimura K, Okamura K, Shen F, Somerville MJ, Tchinda J, Valsesia A, Woodwark C, Yang F, et al.: Global variation in copy number in the human genome. Nature 2006, 444:444-454.
14. Frohling S, Dohner H: Chromosomal abnormalities in cancer. N Engl J Med 2008, 359:722-734.
15. Kolch W, Mischak H, Pitt AR: The molecular make-up of a tumor: proteomics in cancer research. Clin Sci 2005, 108:369-383.
16. Aebersold R, Mann M: Mass spectrometry-based proteomics. Nature 2003, 422:198-207.
17. MacBeatch G, Schreiber SL: Printing proteins as microarrays for high-throughput function determination. Science 2000, 289:1760-1763.
18. Cooper GM, Zerr T, Kidd JM, Eichler EE, Nickerson DA: Systematic assessment of copy number variant detection via genome-wide SNP genotyping. Nat Genet 2008, 40:1199-1203.
19. Tibshirani RJ, Efron B: Pre-validation and inference in microarrays. Stat Appl Genet Mol Biol 2002, 1:Article 1.
20. Nevins JR, Huang ES, Dressman H, Pittman J, Huang AT, West M: Towards integrated clinico-genomic models for personalized medicine: combining gene expression signatures and clinical factors in breast cancer outcomes prediction. Hum Mol Genet 2003, 12:R153-R157.
21. Wang SM, Ooi LL, Hui KM: Identification and validation of a novel gene signature associated with the recurrence of human hepatocellular carcinoma. Clin Cancer Res 2007, 13:6275-6283.
22. Mathew JP, Taylor BS, Bader GD, Pyarajan S, Antoniotti M, Chinnaiyan AM, Sander C, Burakoff SJ, Mishra B: From bytes to bedside: data integration and computational biology for translational cancer research. PLoS Comput Biol 2007, 3:e12.
23. Fridlyand J, Snijders AM, Ylstra B, Li H, Olshen A, Segraves R, Dairkee S, Tokuyasu T, Ljung BM, Jain AN, McLennan J, Ziegler J, Chin K, Devries S, Feiler H, Gray JW, Waldman F, Pinkel D, Albertson DG: Breast tumor copy number aberration phenotypes and genomic instability. BMC Cancer 2006, 6:96.
24. Tomioka N, Oba S, Ohira M, Misra A, Fridlyand J, Ishii S, Nakamura Y, Isogai E, Hirata T, Yoshida Y, Todo S, Kanedo Y, Albertson DG, Pinkel D, Feuerstein BG, Nakagawara A: Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature. Oncogene 2008, 27:441-449.
25. Waters KM, Pounds JG, Thrall BD: Data merging for integrated microarray and proteomic analysis. Brief Funct Genomic Proteomic 2006, 5:261-272.
26. Goble C, Stevens R: State of the nation in data integration for bioinformatics. J Biomed Inform 2008, 41:687-693.
27. Bitton DA, Okoniewski MJ, Connolly Y, Miller CJ: Exon level integration of proteomics and microarray data. BMC Bioinformatics 2008, 9:118.
28. Lanckriet GRG, De Bie T, Cristianini N, Jordan MI, Noble WS: A statistical framework for genomic data fusion. Bioinformatics 2004, 20:2626-2635.
29. Daemen A, Gevaert O, Moor BD: Integration of clinical and microarray data with kernel methods. Conf Proc IEEE Eng Med Biol Soc 2007:5411-5415.
30. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004, 101:811-816.
31. Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, Ferrari M, Hernandez-Boussard T, Brooks JD, Pollack JR: Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007, 67:8504-8510.
32. Machiels JP, Sempoux C, Scalliet P, Coche JC, Humblet Y, Van Cutsem E, Kerger J, Canon JL, Peeters M, Aydin S, Laurent S, Kartheuser A, Coster B, Roels S, Daisne JF, Honhon B, Duck L, Kirkove C, Bonny MA, Haustermans K: Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. Ann Oncol 2007, 18:738-744.
33. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP: Exploration, normalization and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264.
34. Wheeler JMD, Warren BF, Mortensen NJ, Ekanyaka N, Kulacoglu H, Jones AC, George BD, Kettlewell MGW: Quantification of histologic regression of rectal cancer after irradiation. Dis Colon Rectum 2002, 45:1051-1056.
35. Machiels JP, Aydin S, Bonny MA, Hammouch F, Sempoux C: What is the best to predict disease-free survival after preoperative radiochemotherapy for rectal cancer patients: tumor regression grading, nodal status or circumferential resection margin invasion? J Clin Oncol 2006, 24:1319-1321.
36. Adam IJ, Mohamdee MO, Martin IG, Scott N, Finan PJ, Johnston D, Dixon MF, Quirke P: Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 1994, 344:707-711.
37. Quirke P, Durdey P, Dixon MF, Williams NS: Local recurrence of rectal adenocarcinoma due to inadequate surgical resection: histopathological study of lateral tumor spread and surgical excision. Lancet 1986, 2:996-999.
38. Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, Tibshirani R, Botstein D, Altman RB: Missing value estimation methods for DNA microarrays. Bioinformatics 2001, 17:520-525.
39. Gleason DF: Classification of prostatic carcinomas. Cancer Chemother Rep 1966, 50:125-128.
40. Scholkopf B, Tsuda K, Vert JP: Kernel Methods in Computational Biology. Cambridge, MA: MIT Press; 2004.
41. Vapnik V: Statistical Learning Theory. New York: Wiley; 1998.
42. Pochet N, De Smet F, Suykens J, Moor BD: Systematic benchmarking of microarray data classification: assessing the role of nonlinearity and dimensionality reduction. Bioinformatics 2004, 20:3185-3195.
43. Lai C, Reinders MJT, van't Veer LJ, Wessels LFA: A comparison of univariate and multivariate gene selection techniques for classification of cancer datasets. Bioinformatics 2006, 7:235-244.
44. Yang YH, Xiao Y, Segal MR: Identifying differentially expressed genes from microarray experiments via statistic synthesis. Bioinformatics 2005, 21:1084-1093.
45. Li W, Yang Y: How many genes are needed for a discriminant microarray data analysis. In Methods of Microarray Data Analysis. Edited by Lin SM, Johnson KF. Kluwer Academic; 2002:137-150.
46. Hanley JA, McNeil BJ: A method of comparing the areas under receiver operating characteristics curves derived from the same cases. Radiology 1983, 148:839-843.
47. Pavlidis P, Weston J, Cai J, Grundy WN: Gene functional classification from heterogeneous data. In Proceedings of the Fifth Annual International Conference on Computational Biology: April 22-25, 2001; Montreal, Quebec, Canada. New York, NY: ACM; 2001:242-252.
48. Zien A, Ong CS: Multiclass multiple kernel learning. In Proceedings of the 24th International Conference on Machine Learning: June 20-24, 2007; Corvalis, Oregon. New York, NY: ACM; 2007:1191-1198.
49. Zhang W, Park DJ, Lu B, Yang DY, Gordon M, Groshen S, Yun J, Press OA, Vallbohmer D, Rhodes K, Lenz HJ: Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin Cancer Res 2005, 11:600-605.
50. Maihofner C, Charalambous MP, Bhambra U, Lightfoot T, Geisslinger G, Gooderham NJ; The Colorectal Cancer Group: Expression of cyclooxygenase-2 parallels expression of interleukin-1beta, interleukin-6 and NF-kappaB in human colorectal cancer. Carcinogenesis 2003, 24:665-671.
51. Sawhney RS, Sharma B, Humphrey LE, Brattain MG: Integrin ?2 and extracellular signal-regulated kinase are functionally linked in highly malignant autocrine transforming growth factor-?-driven colon cancer cells. J Biol Chem 2003, 278:19861-19869.
52. Rubie C, Frick VO, Pfeil S, Wagner M, Kollmar O, Kopp B, Graber S, Rau BM, Schilling MK: Correlation of IL-8 with induction, progression and metastatic potential of colorectal cancer. World J Gastroenterol 2007, 13:4996-5002.
53. Louhimo J, Carpelan-Holmstrom M, Alfthan H, Stenman UH, Jarvinen HJ, Haglund C: Serum HCG beta, CA 72-4 and CEA are independent prognostic factors in colorectal cancer. Int J Cancer 2002, 101:545-548.
54. Bhatia B, Maldonado CJ, Tang S, Chandra D, Klein RD, Chopra D, Shappell SB, Yang P, Newman RA, Tang DG: Subcellular localization and tumor-suppressive functions of 15-lipoxygenase 2 (15-LOX2) and its splice variants. J Biol Chem 2003, 278:25091-25100.
55. Horvath LG, Lelliott JE, Kench JG, Lee CS, Williams ED, Saunders DN, Grvgiel JJ, Sutherland RL, Henshall SM: Secreted frizzled-related protein 4 inhibits proliferation and metastatic potential in prostate cancer. Prostate 2007, 67:1081-1090.
56. Schwarze SR, Luo J, Isaacs WB, Jarrard DF: Modulation of CXCL14 (BRAK) expression in prostate cancer. Prostate 2005, 64:67-74.
57. Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG, Dobi A, Srivastava S, Petrovics G, Sesterhenn IA: Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008, 21:67-75.
58. Nam RK, Sugar L, Yang W, Srivastava S, Klotz LH, Yang LY, Stanimirovic A, Encioiu E, Neill M, Loblaw DA, Trachtenberg J, Narod SA, Seth A: Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007, 97:1690-1695.
59. Dong Z, Liu Y, Lu S, Wang A, Lee K, Wang LH, Revelo M, Lu S: Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endocrinol 2006, 20:2315-2325.
60. Engers R, Mueller M, Walter A, Collard JG, Willers R, Gabbert HE: Prognostic relevance of Tiam1 protein expression in prostate carcinomas. Br J Cancer 2006, 95:1081-1086.
61. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, Kim R, Tang J, Montie JE, Chinnaiyan AM, Rubin MA, Aster JC: JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res 2004, 64:6854-6857.
62. Silverman RH: Implications for RNase L in prostate cancer biology. Biochemistry 2003, 42:1805-1812.
63. Raje D, Mukhtar H, Oshowo A, Clark CI: What proportion of patients referred to secondary care with iron deficiency anemia have colon cancer? Dis Colon Rectum 2007, 50:1211-1214.
64. Ciardiello F, Tortora G: Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003, 39:1348-1354.
65. Kim TD, Song KS, Li G, Choi H, Park HD, Lim K, Hwang BD, Yoon WH: Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer 2006, 6:211.
66. Uner A, Akcali Z, Unsal D: Serum levels of soluble E-selectin in colorectal cancer. Neoplasma 2004, 51:269-274.
67. Eksioglu EA, Mahmood SS, Chang M, Reddy V: GM-CSF promotes differentiation of human dendritic cells and T lymphocytes toward a predominantly type 1 proinflammatory response. Exp Hematol 2007, 35:1163-1171.
68. Zinzindohoue F, Lecomte T, Ferraz JM, Houllier AM, Cugnenc PH, Berger A, Blons H, Laurent-Puig P: Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer. Clin Cancer Res 2005, 11:594-599.
69. Zhang Y, Lai M, Lv B, Gu X, Wang H, Zhu Y, Zhu Y, Shao L, Wang G: Overexpression of Reg IV in colorectal adenoma. Cancer Lett 2003, 200:69-76.
70. Ahn DH, Crawley SC, Hokari R, Kato S, Yang SC, Li JD, Kim YS: TNF-alpha activates MUC2 transcription via NF-kappaB but inhibits via JNK activation. Cell Physiol Biochem 2005, 15:29-40.
71. Kummola L, Hala J, Kivelamainen JM, Kivela AJ, Saarnio J, Karttunen T, Parkkila S: Expression of a novel carbonic anhydrase, CA XIII, in normal and neoplastic colorectal mucosa. BMC Cancer 2005, 5:41.
72. Gropcke S, Mannone J, Weber B, Staub E, Heinze M, Klaman I, Pilarsky C, Hermann K, Castanos-Velez E, Ropcke S, Mann B, Rosenthal A, Buhr HJ: Differential expression of genes encoding tight junction proteins in colorectal cancer: frequent dysregulation of claudin-1, -8 and -12. Int J Colorectal Dis 2007, 22:651-659.
73. Viet HT, Wagsater D, Hugander A, Dimberg J: Interleukin-1 receptor antagonist gene polymorphism a gs in human colorectal cancer. Oncol Rep 2005, 14:915-918.
74. Kloor M, Michel S, Buckowitz B, Ruschoff J, Buttner R, Holinski-Feder E, Dippold W, Wagner R, Tariverdian M, Benner A, Schwitalle Y, Kuchenbuch B, von Knebel Doeberitz M: Beta2-microglobulin mutations in microsatellite unstable colorectal tumors. Int J Cancer 2007, 121:454-458.
75. Youssef EM, Chen Xq, Higuchi E, Kondo Y, Garcia-Manero G, Lotan R, Issa JPJ: Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. Cancer Res 2004, 64:2411-2417.
76. Muc-Wierzgon M, Nowakowska-Zajdel E, Kokot T, Kozowicz A, Zubelewicz B, Klakla K, Mazurek U, Cholewa K, Wilczok T, Wierzgon J, Sosada K: Genetic disregulation of gene coding tumor necrosis factor alpha receptors (TNFalpha Rs) in colorectal cancer cells. J Exp Clin Cancer Res 2004, 23:651-660.
77. Maeda K, Kang SM, Sawada T, Nishiguchi Y, Yashiro M, Ogawa Y, Ohira M, Ishikawa T, Hirakawa YS, Chung K: Expression of intercellular adhesion molecule-1 and prognosis in colorectal cancer. Oncol Rep 2002, 9:511-514.
78. Ferroni P, Palmirotta R, Spila A, Martini F, Raparelli V, Fossile E, Mariotti S, Del Monte G, Buonomo O, Roselli M, Guadagni F: Prognostic significance of adiponectin levels in non-metastatic colorectal cancer. Anticancer Res 2007, 27:483-489.
79. Miyanaga K, Kato Y, Nakamura T, Matsumura M, Amaya H, Horiuchi T, Chiba Y, Tanaka K: Expression and role of thrombospondin-1 in colorectal cancer. Anticancer Res 2002, 22:3941-3948.
80. Wan Y, Wu N, Wang Z, Ju X, Zhu J, Liu Y, Tang J, Huang Y: Relationship between tissue factor expression and hepatic metastasis and prognosis in rectal cancer. Zhonghua Zhong Liu Za Zhi 2002, 24:378-380.
81. Bethke L, Webb E, Sellick G, Rudd M, Penegar S, Withey L, Qureshi M, Houlston R: Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk. BMC Cancer 2007, 7:123.
82. Cross NA, Chandrasekharan S, Jokonya N, Fowles A, Hamdy FC, Buttle DJ, Eaton CL: The expression and regulation of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbeta1 in prostate cells: relevance to the accumulation of versican. Prostate 2005, 63:269-275.
83. Hudolin T, Juretic A, Spagnoli GC, Pasini J, Bandic D, Heberer M, Kosicek M, Cacic M: Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in cancerous and benign prostatic tissue. Prostate 2006, 66:13-18.
84. Ishii K, Usui S, Sugimura Y, Yoshida S, Hioki T, Tatematsu M, Yamamoto H, Hirano K: Aminopeptidase N regulated by zinc in human prostate participates in tumor cell invasion. Int J Cancer 2001, 92:49-54.
85. Diss JK, Faulkes DJ, Walker MM, Patel A, Foster CS, Budhram- Mahadeo V, Djamgoz MB, Latchman DS: Brn-3a neuronal transcription factor functional expression in human prostate cancer. Prostate Cancer Prostatic Dis 2006, 9:83-91.
86. Cross DS, Burmester JK: Functional characterization of the GDEP promoter and three enhancer elements in retinoblastoma and prostate cell lines. Med Oncol 2008, 25:40-49.
87. Wolfgang CD, Essand M, Lee B, Pastan I: T-cell receptor gamma chain alternate reading frame protein (TARP) expression in prostate cancer cells leads to an increased growth rate and induction of caveolins and amphiregulin. Cancer Res 2001, 61:8122-8126.
88. Descazeaud A, de la Taille A, Allory Y, Faucon H, Salomon L, Bismar T, Kim R, Hofer MD, Chopin D, Abbou CC, Rubin MA: Characterization of ZAG protein expression in prostate cancer using a semiautomated microscope system. Prostate 2006, 66:1037-1043.
89. Sahni A, Simpson-Haidaris PJ, Sahni SK, Vaday GG, Francis CW: Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2). J Thromb Haemost 2008, 6:176-183.
90. Bandyopadhyay S, Wang Y, Zhan R, Pai SK, Watabe M, Iiizumi M, Furuta E, Mohinta S, Liu W, Hirota S, Hosobe S, Tsukada T, Miura K, Takano Y, Saito K, Commes T, Piquemal D, Hai T, Watabe K: The tumor metastasis suppressor gene Drg-1 down-regulates the expression of activating transcription factor 3 in prostate cancer. Cancer Res 2006, 66:11983-11990.